Corporate Overview

EOM Pharmaceuticals was founded with a specific vision to pursue innovative approaches to solving the problems of some of today’s urgent and unmet medical needs. The EOM team is led by an accomplished team of scientists and pharmaceutical executives with a deep legacy in multiple therapeutic areas. EOM’s scientists, clinicians, and business leaders have significant experience in drug development, novel formulations, regulatory strategy, and effective clinical approaches.

EOM’s pipeline is built on proprietary innovations designed to rescue, repair, and restore health. These innovations include the development of the first-and-only dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147, being studied to treat serious retinal diseases without the need for intraocular injection. EOM613 and EOM147 have demonstrated both safety and efficacy in multiple Phase 2 clinical trials.

Latest News

View all news